Xiamen Amoytop Biotech Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

Phase 1

Not yet recruiting

Conditions: Non-alcoholic Steatohepatitis

Interventions: Drug: ACT500 tablets
Drug: Placebo

First Posted Date: 2024-12-04

Last Posted Date: 2024-12-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT06716905

A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Not Applicable

Conditions: Chronic Hepatitis B

Interventions: Drug: Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate

First Posted Date: 2024-11-27

Last Posted Date: 2024-12-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT06707922

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

Phase 2

Recruiting

Conditions: Essential Thrombocythemia

Interventions: Drug: Peginterferon α-2b injection

First Posted Date: 2024-08-14

Last Posted Date: 2024-12-04

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 27

Registration Number: NCT06552429

Locations: 🇨🇳
Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
Union Hospital affiliated to Fujian Medical University, Fujian, China

and more 4 locations

A Trial of YPEG-rhGH in Children With Short Stature

Phase 2

Completed

Conditions: Idiopathic Short Stature
Small for Gestational Age
Turner Syndrome

Interventions: Drug: YPEG-rhGH
Drug: rhGH

First Posted Date: 2023-05-03

Last Posted Date: 2024-01-24

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 78

Registration Number: NCT05838885

Locations: 🇨🇳
The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

and more 16 locations

A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease

Phase 2

Completed

Conditions: Renal Anemia of Chronic Kidney Disease

Interventions: Drug: YPEG-rhEPO

First Posted Date: 2021-05-13

Last Posted Date: 2022-12-16

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT04885647

Locations: 🇨🇳
The First Affiliated Hospital Of Baotou Medical college,Inner Mongolia University Of Science and Technology, Hohhot, Inner Mongol, China
🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
The Second Affiliated Hospital Of Chongqing Medical University, Chongqing, Chongqing, China

and more 14 locations

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Phase 3

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Peginterferon alfa-2b injection
Drug: TDF

First Posted Date: 2021-04-15

Last Posted Date: 2024-03-05

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 475

Registration Number: NCT04846491

Locations: 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳
Traditional Chinese Medicine hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
🇨🇳
The First Hospital of Shanxi Medical University, Taiyuan, China

and more 30 locations

Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

Phase 2

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: Y-shape pegylated somatropin
Drug: Norditropin®
Drug: Norditropin

First Posted Date: 2020-08-14

Last Posted Date: 2024-01-24

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 434

Registration Number: NCT04513171

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Phase 3

Completed

Conditions: Non-Myeloid Malignancy

Interventions: Drug: YPEG-rhG-CSF
Drug: rhG-CSF/PEG-rhG-CSF

First Posted Date: 2020-07-10

Last Posted Date: 2022-02-09

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 398

Registration Number: NCT04466137

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Completed

Conditions: Hepatitis B

Interventions: Drug: Peginterferon Alfa-2B
Drug: Peginterferon Alfa-2A

First Posted Date: 2017-06-08

Last Posted Date: 2021-04-13

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 473

Registration Number: NCT03181113

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Second Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Southwest Hospital, Chongqing, Chongqing, China

and more 25 locations

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Ypeginterferon alfa-2b
Drug: Granulocyte-macrophage colony stimulating factor

First Posted Date: 2015-01-06

Last Posted Date: 2017-01-25

Lead Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT02332473

Locations: 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳
Tongji Hospital, Huazhong University of Science & Technology, Wuhan, Hubei, China

and more 9 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy